Assessing readiness for implementation of psychedelic-assisted mental health therapy, in low- and middle-income countries
Journal of Psychedelic Studies September 4, 2025 Kevin D. Lam, Caroline Griffin, S. Kantipudi et al. 1 citation
Mental health disorders (MHD) rank among the top 10 global causes of disease burden, with significant economic and social costs. Current treatments often have limited efficacy or tolerability, and there has been little recent innovation in treatments. In the past decade, clinical research on Psychedelic-Assisted Therapies (PAT) for treating MHD has increased in high-income countries, while most...